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Epidemiology, pathogenesis, and long-term
course of chronic alcohol dependence
lcoholism is a chronic and relapsing disorder
that imposes enormous costs on society, is one of the
leading causes of death in industrialized countries,and is
among the strongest cost drivers with respect to service
use.
1-5 Thus, the development of successful treatment
approaches and their intensive analysis is of major impor-
tance for public health.Alcohol dependence is one of the
most frequent psychiatric disorders, with a 12-month
prevalence of at least 3%,a lifetime prevalence of 8% to
14%,and a male:female ratio of 2-5:1.
6-11 Both,the course
and the treatment of alcoholism are complicated by a
high rate of comorbid psychiatric disorders,most impor-
tantly personality disorders (approximately 30% to
60%), anxiety (20% to 30%), and mood disorders
(20%).
9,12-15The alcohol-associated burden of disease is
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Alcohol dependence is a frequent, chronic, relapsing, and
incurable disease with enormous societal costs. Thus, alco-
holism therapy and research into its outcome are of major
importance for public health. The present article will: (i)
give a brief overview of the epidemiology, pathogenesis,
and treatment outcomes of alcohol dependence; (ii) intro-
duce the basic principles of outpatient long-term therapy
of alcohol-dependent patients; and (iii) discuss in detail
process-outcome research on Outpatient Long-term
Intensive Therapy for Alcoholics (OLITA). This successful
biopsychosocial approach to the treatment of alcoholism
shows a 9-year abstinence rate of over 50%, a re-employ-
ment rate of 60%, and a dramatic recovery from comor-
bid depression, anxiety disorders, and physical sequelae.
The outcome data are empirically based on treatment
processes that have proven high predictive validity and
give concrete information about where to focus the ther-
apeutic efforts. Thus, process-outcome research on OLITA
can serve for the development of new therapeutic guide-
lines on adapting individual relapse prevention strategies.
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tion and hypertension as a cause of disease and prema-
ture death in Europe.Alcohol consumption causes 6.1%
of deaths,12.3% of lost years caused by premature death,
and 10.7% of all disability-adjusted life years (DALYs)—
this is a measure for the estimation of the number of
healthy life years lost by disease and premature death.
Among young persons, alcohol constitutes the major
cause of death;eg,more than 25% of deaths of European
men between 15 and 29 years of age are attributable to
alcohol.
16,17
Even though the specific causes and complex etiological
processes are only partly understood, five basic factors
can be identified that play a major role for the develop-
ment of alcohol dependence: (i) a strong genetic dispo-
sition, with the estimations of heritability ranging
between 50% and 64%; (ii) irreversible damage of the
so-called motivational or reward system (parts of the
limbic system, above all hippocampus, amygdala, cau-
date nucleus,ventral tegmental area,parts of the frontal
lobe and nucleus accumbens);(iii) specific changes in the
interactions of centrally and peripherally acting neuro-
transmitters and hormones, eg, γ-aminobutyric acid
(GABA), glutamate, dopamine, opioids, epinephrine,
norepinephrine, serotonin, acetylcholine, cannabinoids,
corticotropin-releasing factor (CRF),and neuropeptide
Y. Dysregulations in these transmitter systems are
responsible for acute alcohol intoxication, alcohol
dependence, and the withdrawal syndrome as a conse-
quence of long-term alcohol consumption;(iv) a strong
impairment of the psychobiological stress tolerance;(v)
long years of overlearning of self-destructive behavioral
processes (for review see refs 5,18-62).
Data concerning the long-term course and prognosis of
chronic alcohol dependence are alarming.Longitudinal
studies that investigated follow-up periods between 4
and 35 years identified the following prognostic charac-
teristics:
63-76
• In the long term,alcohol dependence is associated with
significantly increased mortality rates between 15%
and 60%.Thus,the mortality risk for persons with alco-
holism is 2.5 to 9 times higher than for persons without
alcoholism.
•With only 5% to 30% of the samples from beginning of
the studies, a small percentage maintained long-term
abstinence;most patients either relapsed (25% to 60%),
died (15% to 60%),or alternated with phases of absti-
nence,reduced consumption or relapse (10% to  16%).
• Predictors for an unfavorable course are: chronicity,
severe physical sequelae,a comorbid dissocial person-
ality disorder,frequent excessive drinking in the past,
separation from the partner,and unemployment;pre-
dictors of a good prognosis are:stable partnership,re-
employment,long treatment duration,long-term par-
ticipation in self-help groups after a preceding
addiction therapy.
•The recovery process proceeds quickly during the early
years of abstinence.However,recovery takes in total 10
years or longer. The relapse risk is not significantly
decreased nor stable before the third year of absti-
nence.
Outcome research on alcoholism therapy
A review of the current state of outcome research shows
that there have not been any sensational therapeutic
improvements during the last decades.
For more than 30 years, meta-analyses and literature
reviews have consistently shown that alcoholism treatment
is successful and cost-effective in the short term.
77-84 Good
evidence exists that 12-step treatment and diverse pro-
grams of cognitive behavioral therapy (CBT) are equally
effective in achieving abstinence rates of approximately
25% to 30% during the year after treatment (for exam-
ples see refs 85,86). However, most treatment studies
demonstrate substantial methodological shortcomings.
Treatment outcomes are normally based on subjective
statements of patients concerning their state of current
alcohol consumption and abstinence.On the rare occa-
sions that studies have corroborated subjective outcome
data with objective laboratory data,the results are rather
inexact and fragmented. Finally, the results of the few
valid investigations of long-term outcome are inconsis-
tent:objective information on drinking status indicates
that only 6% to 18% of patients are abstinent at 2-year
follow-up.
87 In contrast,studies relying on self-report data
suggest that approximately 30% of patients are abstinent
2 to 3 years after treatment.
88,89
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Selected abbreviations and acronyms
HAQ Helping Alliance Questionnaire
OLITA Outpatient Long-term Intensive Therapy for
Alcoholics
TOPPS Therapy Orientation by Process Prediction Score
VAMP Video-Assisted Monitoring of Psychotherapeutic
Processes in Chronic Psychiatric DiseaseThere is no evidence for a sufficient efficacy of a primar-
ily pharmacotherapeutic treatment of alcoholism.Whereas
the alcohol deterrent disulfiram has proven to be an
adjunctive of psychotherapeutic alcoholism therapy for
more than 50 years,
90-95 many studies have found efficacy
of the anticraving substances acamprosate and naltrexone
over the last 15 years.
96-100 However,the results of a recent
large-scale multicenter study challenge the additional effi-
cacy of anticraving medications over behavior therapy.
101
Anton et al studied treatment outcomes of a large sample
(N=1383) of alcohol-dependent patients who were treated
for 16 weeks and re-examined after 12-month follow-up.
The authors investigated whether different combinations
of naltrexone,acamprosate,and cognitive behavior ther-
apy differ with regard to the outcome “number of absti-
nent days.”Whereas acamprosate did not show any effi-
cacy, the combinations “naltrexone plus medical
management”and “naltrexone plus medical management
and behavior therapy”were not more successful than a
simple combination of behavior therapy,placebo medica-
tion,and medical management.
101
A sobering conclusion can be drawn when interpreting
these results critically,and taking into account a recent
literature review that has compiled studies showing that
the alcohol deterrent disulfiram is superior to the newer
anticraving medications.
90 Even though seemingly inno-
vative psychotherapy concepts have been presented and
praised every now and then,and a number of new med-
ications have been launched,until now no treatment con-
cept has been found that yields superior outcome data
than the well-known and clinically often practiced com-
bination of broad-spectrum behavior therapy and med-
ical management.
Considering the high prevalence and chronicity,the fluc-
tuating and devastating course,the increased mortality,
and the low long-term abstinence rates, a challenging
understanding of alcoholism treatment emerges.Alcohol
dependence is among a group of chronic diseases such as
chronic polyarthritis,hypertension,bronchial asthma,and
diabetes mellitus that require a flexible, intensive, and
lifelong treatment.
4,94,102 Consequently,the question arises
as to why therapists,therapy researchers,and social insur-
ance agencies still recommend the so-called brief inter-
ventions as seemingly successful therapeutic options for
individuals with alcohol dependence.Brief interventions
may constitute treatment alternatives for individuals with
risky consumption and alcohol abuse, and for these
patients they can achieve outcomes with medium effect
sizes.However,they are ineffective in the treatment of
alcohol-dependent patients.
103-105
Principles of an outpatient long-term 
treatment of alcohol-dependent patients
The basic principles of an innovative biopsychosocial
treatment approach are derived from the evidence of epi-
demiology,pathogenesis,course,and treatment outcome
of alcohol dependence
102,106,107:
• Strict abstinence orientation.Alcohol dependence is an
irreversible and incurable disease. Only consequent
long-term abstinence can stop disease progression and
enhance the recovery process.Treatment approaches
that aim at so-called “controlled drinking” are con-
traindicated for alcohol-dependent patients.
• Supportive,nonconfronting therapist behavior.During
the first months of abstinence, alcohol-dependent
patients demonstrate a strong impairment of the psy-
chobiological stress system which only recovers slowly.
Whereas confronting and emotionally stressful thera-
peutic interventions like cue exposure are harmful,the
supportive,client-centered,and cognitive behavioral
therapeutic strategies have proven efficient.
• Chronic disease—intensive,lifelong treatment.Chronic
alcohol dependence is associated with a strong genetic
disposition,irreversible neurobiological damage,and
decades of self-destructive learning processes. Only
long-term and comprehensive therapies,followed by
lifelong attendance of checkup sessions and self-help
group participation,can guarantee long-term recovery.
• A relapse is an emergency. Alcohol dependence is a
severe psychiatric disease demonstrating high rates of
physical and psychiatric comorbid disorders, a vast
number of social problems,and a significantly increased
mortality risk.Similarly to relapses in other severe dis-
eases, an alcohol relapse has to be interpreted as an
emergency that requires immediate crisis intervention.
Any delay clearly means a poorer prognosis.
OLITA: a successful biopsychosocial approach
to the treatment of alcoholism
Outpatient Long-term Intensive Therapy for Alcoholics
(OLITA) is a four-step biopsychosocial outpatient ther-
apy program for severely affected alcohol-dependent
patients,aiming at immediate social reintegration within
the sheltered setting of psychotherapeutic treatment and
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401medical care. Therefore, basic elements of psychiatric
patient care, client-centered and cognitive-behavioral
psychotherapy,as well as classical addiction therapy,are
integrated into a comprehensive,intensive and long-term
treatment approach (Tables I and II). In order to take
into account both the impaired stress tolerance of the
patients during early abstinence and the chronicity of the
disease,the OLITA concept combines high intensity (ie,
Clinical research
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• High-frequency short-term individual therapeutic contacts
Structured, guarded attachment by supportive, nondemanding short-term contacts; initially 15 minutes daily, including weekends and 
holidays; slow tapering off of contact frequency aiming at regular and permanent attendance of weekly group sessions.
• Emergency service and crisis interventions
In case of emergency, patients and their relatives can contact OLITA round the clock on any day of the year.
• Social reintegration and home visits
Specific assistance in rearranging a social network which supports an abstinent lifestyle; explicit cooperation with family members and 
friends; family and marital sessions; advice and support regarding occupation, authorities, housing problems, moving, job-seeking, financial 
and legal problems.
• Induction of alcohol intolerance
Use of calcium carbimide (Colme®) or disulfiram (Antabuse®), so-called alcohol deterrent medication (inhibition of the alcohol-metabolizing 
enzyme acetaldehyde dehydrogenase leads in case of alcohol consumption to accumulation of toxic acetaldehyde resulting in an "inner 
poisoning," the so-called "disulfiram-ethanol reaction," comprising extensive flushing, hyper- or hypotension, tachycardia, nausea, vomiting, 
anxiety).
• Introduction of control factors
Regular urine and blood analyses for alcohol and other drugs of abuse; if necessary, additional breath tests. Supervised intake of deterrent 
medication and explicit exploitation of its psychological effects.
• Aggressive aftercare
Aggressive therapeutic interventions to immediately interrupt beginning and to prevent threatening relapses. Patients who miss a therapeutic 
contact are called on to continue therapy or to restart abstinence; examples of aggressive aftercare are spontaneous house visits, telephone 
calls, and involvement of close friends/relatives.
• Therapist rotation
An interdisciplinary cooperating team of 6 to 7 therapists is treating the patients (supervising psychiatrist, psychologist, physician, social 
worker, nurse and MD or PhD students). All therapists are equally responsible for all patients. The classical fixation of a single patient to a 
single therapist is abandoned. 
Table I. The main therapeutic elements of OLITA, Outpatient Long-term Intensive Therapy for Alcoholics.
• Inpatient period: Detoxification
2-3 weeks; daily individual sessions, 15 minutes each;
disulfiram, 100 mg daily, or calcium carbimide, 50 mg daily. 
• Outpatient period I: Intensive phase
3 months; daily individual sessions, 15 minutes each; 
disulfiram, 100 mg daily, or calcium carbimide, 50 mg daily.
• Outpatient period II: Stabilizing phase
3-4 months, according to individual need; 3 times a week individual sessions, 15 minutes each; disulfiram, 400 mg, 3 times a week.
• Outpatient period III: Weaning-off phase
6 months; twice a week individual sessions, 30 minutes each;
disulfiram, 400 mg, twice a week.
• Outpatient period IV: Aftercare phase
12 months; once-weekly group session; initially weekly individual sessions (30 minutes) which are gradually reduced; disulfiram, 400 mg, 
once a week; tapering off between months 13 and 20, individual extension possible.
Table II. Practical realization of the treatment program.Outpatient long-term intensive therapy for alcoholics - Krampe et al Dialogues in Clinical Neuroscience - Vol 9 . No.4 . 2007
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high frequency of therapy contacts) and long duration of
therapy.
26,108 Following inpatient detoxification,the treat-
ment extends over 2 years. The OLITA pilot study
started in 1993 and was terminated successfully in 2003
after 10 years and the completion of 180 patients
assigned to recruitment cohorts 1-6.
94,106The main thera-
peutic elements of OLITA are:(i) frequent contacts,ini-
tially daily,with a slow reduction of contact frequency up
to the end of the second year;(ii) therapist rotation;(iii)
support of social reintegration and aggressive aftercare;
(iv) induction of alcohol intolerance through application
of alcohol deterrents (inhibitors of acetaldehyde dehy-
drogenase);(v) explicit control:supervised intake of alco-
hol deterrents and regular urine analysis for alcohol and
other drugs of abuse.The therapeutic phases of OLITA
consist of the inpatient period (detoxification; 2 to 3
weeks;daily individual sessions,15 minutes),the outpa-
tient period I (intensive phase;3 months;daily individual
sessions,15 minutes),the outpatient period II (stabiliz-
ing phase; 3 to 4 months according to individual need;
three times a week individual sessions,15 minutes),the
outpatient period III (weaning-off phase;6 months;twice
a week individual sessions,30 minutes),and outpatient
period IV (aftercare phase; 12 months; once weekly
group session;initially once weekly individual session,30
minutes,which is gradually tapered off).After comple-
tion of the 2 years of therapy, patients participate in
weekly to quarterly follow-up contacts and are offered
to make use of both the emergency service and the crisis
interventions of the therapeutic team.
Patients in the OLITA program: sociodemographic
and addiction severity characteristics 
Inclusion criteria for OLITA are alcohol dependence
according to DSM-IV,residence nearby,and health insur-
ance-covered treatment costs.Exclusion criteria are pres-
ence of moderate to severe dementia and acute concur-
rent abuse or dependence on substances other than
alcohol (with the exception of caffeine and nicotine).
Thus far,180 alcoholics (144 men,36 women) have been
treated with a 7-year follow-up success rate of over 50%
abstinent patients despite a “negative selection,” with
regard to severity of alcohol dependence,comorbidity,
and social detachment, upon entering the program.
Patients were on average 44±8 years old,had a duration
of alcohol dependence of 18±7 years,approximately 7±9
prior inpatient detoxification treatments,and 1±1 failed
inpatient long-term therapy.Almost 60% of the patients
were unemployed.Psychiatric comorbidity amounted to
80%.About 60% of the patients suffered from severe
sequelae of alcoholism,such as polyneuropathy,chronic
pancreatitis, or liver cirrhosis. To illustrate addiction
severity in our population,representative scores of the
European Addiction Severity Index
109,110 were 0.58 (±0.38)
for medical status,0.56 (±0.47) for economic status,0.51
(±0.37) for job satisfaction,0.83 (±0.11) for alcohol use,
0.59 (±0.30) for family relationships,and 0.46 (±0.21) for
psychiatric status.
Long-term treatment outcomes 
Considering this severely affected population of alcoholics,
the long-term success rate of OLITA is incredibly high:
More than 50% of the patients remain abstinent over up
to 7 years of post-treatment follow-up (Figure 1).Based on
this high abstinence rate,a tremendous improvement in
psychological, biological, and social parameters of this
patient group could be achieved.The unemployment rate
of OLITA patients declined to 22% in an area (Göttingen)
with a general unemployment rate of 17% (Figure 2),and
the comorbid psychiatric disorders anxiety and depression
decreased from approximately 60% to 13%.
76,94
Additionally, patients had a clear decrease in physical
sequelae of alcoholism, ranging from liver disease to
polyneuropathy.Figure 3 a,b and c illustrate the highly sig-
Figure 1. The cumulative abstinence probability during the 9-year
study is .52 for the complete sample (N=180); Kaplan-
Meier estimates; cases are censored if they have not
experienced a relapse by the end of follow-up.
Probability of being free of relapse
For comparison:
best results reported in the literature
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1.0nificant reduction in psychiatric comorbidity.Shown are all
comorbid disorders (Figure 3a),anxiety disorders (Figure
3b),and mood disorders (Figure 3c) in percentage of the
study population from month 1 of therapy to 2 years,ie,the
termination of the program.The global decrease of comor-
bid disorders during therapy is characterized by two spe-
cific features of the recovery process.Firstly,anxiety disor-
ders show a delayed remission, ie, they do not change
significantly until the first year of therapy.Secondly,the
early remission of mood disorders during the first 6 months
harbors the risk of reccurence of major depression during
long-term abstinence. These data suggest that effective
treatment of dual diagnosis patients comprises two basic
elements:(i) long-term duration as prerequisite of gradual
remission of anxiety and protective factor against recidi-
vism of mood disorders; (ii) comprehensive and careful
integration of dual diagnosis interventions considering
temporary impairments of coping skills and the imminent
danger of overtaxing current patient resources. Simple
addition of some treatment elements for comorbid disor-
ders to short-term alcoholism therapy has no effect
111 or
even causes a negative outcome.
112
A case-control study
Compared with thoroughly paralleled case controls who
participated in alternative treatment programs,the out-
come of OLITA patients is significantly better.
102
Clinical research
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Figure 2. Employment of OLITA patients (N=180); ** P<0.0001
versus situation upon entering OLITA. The gray shaded
area shows the proportion of patients who were work-
ing before OLITA, but who had received official warn-
ings from their employers.OLITA, Outpatient Long-term
Intensive Therapy for Alcoholics
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Figure 3. Two-year course of comorbid axis I disorders during
OLITA, Outpatient Long-term Intensive Therapy for
Alcoholics
** P<0.01; * P<.05, P-values were adjusted for multiple
comparisons according to the stepwise rejecting Holm
procedure.
121
Figure 3a. Two-year course of all comorbid axis I disorders.
Figure 3b. Two-year course of anxiety disorders. 
Figure 3c. Two-year course of mood disorders. 
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*Separate analysis of lapses (intake of alcohol followed by
immediate cessation of drinking and continuation of the
OLITA program) and relapses (intake of alcohol fol-
lowed by “malignant” continuation of drinking) in
OLITA patients reveals that the “true relapse rate” in
OLITA patients is 30% as compared with 70% in con-
trols.Relapses plus lapses in OLITA patients amounted
to 60%.Thus,the immediate stop of lapses by means of
crisis interventions has prevented the progression into
relapses for 30% of the patients.
Mechanisms of recovery and irreversibility 
The OLITA program offers the unique possibility of fol-
lowing a well defined population of alcoholics over a long
period of strictly controlled alcohol abstinence.In this
ideal setting, we were able to study alcohol-induced
pathology,as well as kinetics and mechanisms of recov-
ery.Topics investigated include chromosomal aberrations,
hematopoietic factors and circulating blood cells,stress
hormones,sexual function and sex hormones,as well as
neurocognitive functioning.Recently,we reported per-
sistent alterations in many neuroendocrinological para-
meters,for example enduring disturbances of water/elec-
trolyte homeostasis and thirst.These findings may pre-
pare the ground for future pharmacological therapies.
The underlying mechanisms of irreversibility could be
directly or indirectly related to the phenomenon of
dependence as well as of addictive behavior.
23,26,31-35,51,113
Figure 4 shows the diurnal profile of epinephrine after
1 and 12 weeks of alcohol abstinence as an example of
the biological basis of the patients' impaired stress toler-
ance during early abstinence.At both time points,data
were obtained on three consecutive days from 7 AM to
3 PM from patients and controls in permanent supine
position. Alcohol-dependent patients demonstrate
extremely high levels of epinephrine at the beginning of
abstinence that are still significantly higher than levels of
healthy control subjects after 3 months of controlled
abstinence (difference between alcohol-dependent
patients and healthy control subjects: P<.0001 for the
upper row, P<.01 for the lower row; N=11 for each
group).The extent to which the stress response of the
alcohol-dependent patients is impaired can be seen from
Outpatient long-term intensive therapy for alcoholics - Krampe et al Dialogues in Clinical Neuroscience - Vol 9 . No.4 . 2007
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Figure 4. Diurnal profile of epinephrine during course of alcohol abstinence (see text for details).
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90the consistently higher stimulation of their epinephrine
levels on all of the 6 days of assessment as compared with
control subjects at the time point when the intravenous
cannula was inserted (at 7 AM).
Personality disorder and chronicity of addiction as
potent independent predictors of an unfavorable 
treatment outcome 
A central issue of therapy research is to estimate the
intensity of treatment needed on the basis of addiction
severity of individuals. This approach is based on the
assumption that patients whose addiction is less severe
than others’ might also benefit from less intensive treat-
ment,whereas patients whose addiction is more severe
need a more intensive therapy. However, it is far from
clear which variables within the broad range of substance
use data constitute the essential features of addiction
severity.
14,69,86The OLITA setting prepared the ground for
a prospective longitudinal study that examined which
components of addiction severity predict time to relapse
for a subsample of 112 patients during 4-year follow-up.
108
Among the various analyzed sociodemographic,psychi-
atric,and alcoholism-related patient characteristics,only
the presence of a personality disorder (Wald=7.83,df=1,
P=.005) and chronicity of addiction (Wald=5.17, df=1,
P=.023) were independently associated with a decrease
of cumulative 4-year abstinence probability.Chronicity
was defined as the percentage of a patient’s lifetime that
he or she has been addicted (ie,duration of dependence
divided by age at the beginning of therapy).As illustrated
in Figure 5,patients with a comorbid personality disor-
der and/or higher chronicity of addiction had a lower
abstinence probability and a shorter time to relapse than
patients without personality disorder and/or with lower
chronicity.The four abstinence curves differ significantly
(Breslow statistic=10.36,P=.02).Pairwise single compar-
isons of abstinence curves show that patients with both
predictors are more at risk to relapse (.53,N=25,black
line) than patients with no personality disorder and only
low chronicity (.93,N=14,red line) (Breslow statistic=5.5,
P=.02). Abstinence curves of patients who are handi-
capped only by personality disorder (.59, N=23, green
line) or only by high chronicity (.60, N=11, gray line)
approximate the abstinence curve of patients with both
risk factors, indicating that these predictors indepen-
dently cause a decrease of cumulative abstinence proba-
bility.
Therapist rotation: a major element of OLITA
Apart from the regained quality of life of these patients,
the general health care cost reduction is enormous.How
can we explain the unusual success of our very struc-
tured, intensive, and comprehensive long-term treat-
ment? A major "mechanism of action" of OLITA seems
to be the therapist rotation.
107 This element of OLITA
represents a revolution in psychotherapy.The fact that
six to seven therapists are equally responsible for each
patient translates the ordinary two-way relation between
therapist and patient into a most efficient multiway ther-
apeutic network.Therapists stick to the rules of the pro-
gram and the ideas of alcoholism treatment realized
within the concept (congruence) and frequently repeat
these rules and ideas (repetition).Thereby, a variety of
individual therapists with a variety of different thoughts
create a therapeutic atmosphere characterized by vivid
and multifaceted variation.We hypothesize that these
specific factors activate common factors of psychother-
apy and that,as an element of OLITA,therapist rotation
has a major contribution to its success.
Clinical research
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Figure 5. Prediction of cumulative abstinence probability during
4-year follow-up (Kaplan-Meier presentation).
Interaction of the predictors personality disorder and
chronicity (analysis of extreme groups). 
Days from first outpatient contact
Chronicity < .35,
No personality disorder
Chronicity < .35,
Personality disorder
Chronicity ≥ .49,
No personality disorder
Chronicity ≥ .49,
Personality disorder
A
b
s
t
i
n
e
n
c
e
 
p
r
o
b
a
b
i
l
i
t
y
0
0.8
0.7
0.6
0.5
1.0
0.9
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0.5How can we prove efficacy in a psychotherapeutic 
setting?
In contrast to pharmacological agents,psychotherapeu-
tic effects are much more difficult to define or to mea-
sure. In addition, quality control for psychotherapy is
widely missing.Therefore,and also to prove our hypothe-
ses of how OLITA works,we have developed the Video-
Assisted Monitoring of Psychotherapeutic Processes in
Chronic Psychiatric Disease (VAMP).This diagnostic
measure is a standardized,manualized,and video-based
observational system that focuses mainly on the patients’
behavior and makes it possible to assess treatment
processes based on transcribed video recordings of ther-
apy sessions.
114 The scales evaluated in the VAMP are
grouped into seven modules:(i) common psychothera-
peutic factors;(ii) addictive behavior;(iii) disease con-
cept; (iv) working atmosphere; (v) psychopathological
symptoms; (vi) therapeutic alliance; and (vii) problem
solving.A total of 64 patients have been analyzed over
the past 4 years using the VAMP. Each patient had 17
videotapes of psychotherapeutic sessions within the 2
years of OLITA recorded.These videos are the basis of
both,a macroanalytical and a microanalytical evaluation
of therapeutic processes and their influence on long-term
outcome. An ongoing project explores the use of the
VAMP in a prospective longitudinal study investigating
(i) processes of change during the first year of OLITA;
(ii) associations between therapeutic processes and
essential outcome variables (eg, abstinence, relapse,
addiction severity,course of comorbidity,and neuropsy-
chological regeneration).
114 Therefore, treatment
processes have been investigated at three time-points,t1
(week 3),t2 (month 6),and t3 (month 12) during the first
year of OLITA.
Reliability analyses show that the scales of the VAMP
have high interjudge reliability (median intraclass coeffi-
cient of 0.80) and internal consistency (median Cronbach's
α 0.81).The construct validity is indicated by pronounced
intercorrelation patterns of theoretically associated spe-
cific factors.Figures 6 and 7 demonstrate two examples.
Relapse alertness (Figure 6) is strongly correlated with talk
about relapse risk,disease concept,analytic processing and
reflexion, experience of resources, as well as with func-
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Figure 6. Intercorrelational pattern of the VAMP scales at the beginning of therapy (n=64); relapse alertness (central construct, light
blue) shows correlations of different sizes with process variables belonging to the groups of common psychotherapeutic fac-
tors (light gray), problem processing (dark gray) as well as addictive behavior (dark blue).
OLITA, Outpatient Long-term Intensive Therapy for Alcoholics; VAMP: Video-Assisted Monitoring of Psychotherapeutic Processes In Chronic
Psychiatric Disease
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lems.However,correlations are only medium-sized with
self-disclosure and implicit craving. Most interestingly,
relapse alertness is only weakly associated and nearly inde-
pendent of explicit craving,functional and dysfunctional
problem solving of past problems and both general and
abstinence self-efficacy.To perform construct validation of
the VAMP therapeutic alliance scales (Figure 7),associa-
tions with the self-report measure Helping Alliance
Questionnaire (HAQ) were analyzed.
115,116 This 11-item
questionnaire has well-established psychometric proper-
ties,is available as a patient form and a therapist form and
measures how patient and therapist have experienced the
quality of therapeutic alliance during the session just con-
ducted.It is based on two underlying components of the
therapeutic alliance,support by the therapist and collabo-
rative teamwork with the therapist regarding treatment
goals and tasks.In the present study,the HAQ was admin-
istered directly after a therapy session,and neither patient
nor therapist or VAMP raters were allowed to inspect
each others' ratings. The three VAMP scales, working
atmosphere,therapeutic alliance-patient and therapeutic
alliance-therapist are highly correlated, suggesting an
underlying common factor. Compared with the rather
small associations between patient,therapist,and observer
alliance ratings that are reported in the general psy-
chotherapy literature
117 and in recent addiction therapy
studies (eg,refs 118-120),both patient and therapist HAQ
scores in our study show considerably higher correlations
with each other and with VAMP observer ratings.This
higher congruence,together with remarkably stable and
high scores over 12 months in all used alliance measures,
114
lead us to the speculation that the multiple relationships
developed in the setting of therapist rotation might con-
stitute a stronger therapeutic alliance than the two-way
relationships in the dyadic therapy setting.Although these
data are not yet a clear proof that therapist rotation is a
major factor contributing to the long-term success of
OLITA,they are the first empirical evidence on therapist
rotation and may stimulate future investigations of this
rather unexplored research topic.
Treatment processes in clinical practice: where to start?
Therapists in the addiction field daily face the difficulty
to decide which of the many dysfunctional processes of
their patients have priority and should be focused on at
first. By integrating the VAMP scales with the highest
predictive validity, the composite score Therapy
Orientation by Process Prediction Score (TOPPS) was
constructed.It includes the process variables experience
of resources, abstinence self-efficacy, implicit craving,
relapse alertness,relapse risk,disease concept,dysfunc-
tional therapeutic engagement,and dysfunctional prob-
lem solving of current problems.The TOPPS strongly
predicts 4-year abstinence probability at any of the 3
time-points (P<0.001).This result suggests employing the
TOPPS in addiction therapy as a treatment guideline for
adapting individual relapse prevention strategies.
Therapists and addiction counselors can evaluate their
patients according to the eight processes after individual
therapy sessions as well as in team sessions.The ratings
may be employed in form of a checklist that serves as a
practical tool to plan,evaluate,reschedule,and regulate
the course of therapy. Problems in one or more of the
eight processes indicate to what extent a patient's current
behavior constitutes a long-term risk factor for alcohol
relapse.As a consequence,individually tailored relapse
prevention strategies that target specifically the improve-
ment of the problematic processes should be integrated
into the treatment plan.
For possible interventions,a plethora of therapeutic ele-
ments are available in comprehensive addiction therapy,
all of them realized within the OLITA program,eg,moti-
vational interventions during inpatient detoxification,
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Figure 7. Aspects of therapeutic alliance in OLITA: Correlational
pattern between different observer-rated (dark blue,
VAMP scales) and self-reported (light blue, HAQ) mea-
sures of therapeutic alliance at the beginning of ther-
apy (n=64). 
OLITA, Outpatient Long-term Intensive Therapy for Alcoholics;
VAMP: Video-Assisted Monitoring of Psychotherapeutic
Processes In Chronic Psychiatric Disease; HAQ, Helping Alliance
Questionnaire.
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smooth transition from inpatient to outpatient treatment,
high-frequency short-term individual therapeutic contacts,
supportive psychotherapy during the first 6 months of
abstinence,therapist rotation,social support,case man-
agement, regular urine and blood tests for alcohol and
other drugs of abuse,supervised intake of alcohol deter-
rents,house visits,crisis interventions and assistance round
the clock in case of emergency,“aggressive aftercare,”cop-
ing and problem-solving skills training including functional
analyses,psychoeducation,and restructuring of dysfunc-
tional thinking, eclectic cognitive-behavioral and psy-
chopharmacological treatment of concurrent mental dis-
orders, marital and family therapy, slow tapering of
therapeutic contacts and weekly group sessions during the
second year of treatment.
Conclusions and clinical implications
Alcohol dependence is a chronic,relapsing,and incurable
disease that belongs to the most frequent psychiatric dis-
orders.Personality disorder and chronicity constitute the
essential features of addiction severity and result in low
abstinence rates of short- and medium-term therapies
after extended follow-up.A new understanding of alco-
holism therapy recognizes alcohol dependence as a
chronic disease such as hypertension, chronic pol-
yarthritis,bronchial asthma,and diabetes mellitus.Similar
to these diseases,alcohol dependence has to be treated
with an unusually intensive biopsychosocial approach.
Only comprehensive, integrated, and structured long-
term therapy with a strict abstinence orientation, fol-
lowed by lifelong attending of checkup sessions and self-
help group participation will guarantee long-term
recovery.
OLITA shows a 9-year abstinence rate of over 50%,a re-
employment rate of 60%,and a dramatic recovery from
comorbid depression, anxiety disorders, and physical
sequelae.These outcome data are empirically based on
treatment processes that have proven high predictive
validity and give concrete information about where to
focus the therapeutic efforts. Thus, process-outcome
research on OLITA can serve for the development of
new therapeutic guidelines for adapting individual
relapse prevention strategies. ❏
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Terapia intensiva a largo plazo para 
pacientes alcohólicos ambulatorios (OLITA):
una aproximación biopsicosocial exitosa
para el tratamiento del alcoholismo
La dependencia al alcohol es una enfermedad fre-
cuente, crónica, recurrente e incurable con enormes
costos sociales. Por lo tanto, la terapia del alcoho-
lismo y la investigación acerca de la evolución son de
la mayor importancia para la salud pública. El pre-
sente artículo: 1) dará una breve visión acerca de
cómo ha evolucionado la epidemiología, la patogé-
nesis y la terapéutica de la dependencia al alcohol, 2)
introducirá los principios básicos del tratamiento a
largo plazo de pacientes ambulatorios con depen-
dencia al alcohol y 3) discutirá en detalle la investi-
gación del proceso y evolución de la Terapia Intensiva
a Largo Plazo de Pacientes Alcohólicos Ambulatorios
(OLITA). Esta exitosa aproximación biopsicosocial al
tratamiento del alcoholismo muestra un porcentaje
de abstinencia a nueve años sobre el 50%, una fre-
cuencia de reincorporación laboral del 60% y una
importante recuperación de la depresión, los tras-
tornos de ansiedad y las secuelas físicas comórbidas.
Los datos de la evolución se basan empíricamente en
procesos terapéuticos que han probado una alta vali-
dez predictiva y dan información concreta acerca de
dónde dirigir los esfuerzos terapéuticos. De esta
forma, la investigación del proceso-evolución de
OLITA puede servir para el desarrollo de nuevas guías
terapéuticas para la adaptación individual a las estra-
tegias para la prevención de recaídas. 
OLITA (Outpatient Long-term Intensive
Therapy for Alcoholics) : une approche 
biopsychologique réussie du traitement de
l’alcoolisme
La dépendance alcoolique est une maladie fréquente,
chronique, récidivante et incurable entraînant
d’énormes coûts sociétaux. Le traitement de l’alcoo-
lisme et la recherche sur les effets de ce traitement
revêtent donc une importance majeure en termes de
santé publique. L’article qui suit: (i) propose un bref
aperçu de l’épidémiologie, de la pathogenèse et des
résultats thérapeutiques de la dépendance alcoolique ;
(ii) introduit les principes de base du traitement à
long terme en ambulatoire des patients alcooliques ;
(iii) discute en détail des résultats du programme thé-
rapeutique intensif OLITA (Outpatient Long-term
Intensive Therapy for Alcoholics). Cette approche bio-
psychologique du traitement de l’alcoolisme s’est avé-
rée efficace, montrant un taux d’abstinence de plus
de 50 % sur 9 ans, un taux de réemploi de 60 % et
une récupération très importante à la suite d’une
dépression comorbide, de troubles anxieux ou de
séquelles physiques. Les résultats, basés empirique-
ment sur des procédures thérapeutiques dont la
valeur prédictive élevée a été démontrée, indiquent
concrètement où porter les efforts thérapeutiques.
Ainsi, la recherche concernant les effets des processus
de la prise en charge OLITA peut servir à l’élaboration
de nouvelles recommandations thérapeutiques pour
adapter en les individualisant les stratégies de pré-
vention de la rechute.
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